CD274 and non-small cell lung carcinoma: At present, the PD-L1 expression level, tumor mutation burden (TMB), microsatellite instability (MSI), and DNA mismatch repair (dMMR) are also used as indicators to evaluate the efficacy of ICIs in treating NSCLC patients.